Atypical antipsychotics (AAs) are commonly used in the treatment of schizophrenia and are often preferred as first‐line therapy over typical antipsychotics (TAs) due to their lower risk of extrapyramidal side… Click to show full abstract
Atypical antipsychotics (AAs) are commonly used in the treatment of schizophrenia and are often preferred as first‐line therapy over typical antipsychotics (TAs) due to their lower risk of extrapyramidal side effects. Both groups are efficacious in treating symptoms of schizophrenia, but increasing research has highlighted AAs as being associated with a risk of developing dyslipidaemia. Existing research has pointed to the need for more data focusing on the effects of individual AAs on dyslipidaemia in this population.
Journal Title: Neuropsychopharmacology Reports
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!